Brambles Limited (ASX:BXB) Prices €500 Million Green Bond
Brambles Limited (ASX:BXB) prices a €500 million Green Bond to support its sustainability and circular business initiatives.
Tag: Investor Relations
James Bay Minerals (ASX:JBY) Commences Drilling at Independence Project
James Bay Minerals (ASX:JBY) begins a 4,000m drill program at Independence Project’s Rebel Trend, targeting significant gold resource growth.
Desert Metals Limited (ASX:DM1) Commences Drilling Programs and Secures Placement
Desert Metals (ASX:DM1) initiates comprehensive drilling programs in Côte d’Ivoire and secures AUD 3.25m funding through placement.
Healius (ASX:HLS) Announces Pathology Strategy and $300M Dividend at Investor Day 2025
Healius (ASX:HLS) reveals a new pathology strategy and a $300 million special dividend during Investor Day 2025.
Teaminvest Private Group Limited (ASX:TIP) Extends Share Buy-Back Program
Teaminvest Private Group Limited (ASX:TIP) extends its share buy-back program for another 12 months, authorising up to 10% of issued capital.
Resolution Minerals (ASX:RML) Acquires High-Grade Antimony-Gold Portfolio
Resolution Minerals (ASX:RML) acquires high-grade antimony and gold projects in NSW and QLD, enhancing its strategic mining portfolio.
Godolphin Resources (ASX:GRL) Raises ~$1.0M Through Strategic Placement
Godolphin Resources (ASX:GRL) raises ~$1.0M through a strategic placement to advance metallurgical and exploration activities at Lewis Ponds project.
BMG Resources (ASX:BMG) Accelerates Gold Exploration in Western Australia
BMG Resources (ASX:BMG) accelerates gold exploration at Bullabulling and Invincible Projects, leveraging high-grade discoveries and strategic acquisitions.
Austin Metals Limited (ASX:AYT) Announces $1.25M Capital Raising to Boost Exploration
Austin Metals Limited (ASX:AYT) raises $1.25M to enhance exploration at key WA gold and copper projects.
Prescient Therapeutics (ASX:PTX) Initiates Phase 2a PTX-100 Clinical Study
Prescient Therapeutics (ASX:PTX) initiates Phase 2a clinical study for PTX-100, marking a significant milestone in treating Cutaneous T-Cell Lymphoma.